TREAT U is aware of the importance of building a strong Intellectual Property portfolio. While advancing our platforms to market, we are careful in ensuring a dominant intellectual property position.
TREAT U’s pipeline is endowed of a combination of patent, regulatory, and scientific barriers to generic drug competition.
TREAT U has developed and licensed inventions from prominent institutions such as the University of Coimbra and the Center for Neurosciences and Cell Biology.
PEGASEMP™ is a proprietary platform, capable of adding new value to old drugs, creating a strong and long market exclusivity profile to products otherwise going off-patent.
ISSUED U.S. PATENTS
US 8,231,895 B2 Targeted delivery to human diseases and disorders
US 8,529,944 Targeted delivery to human diseases and disorders
US 8,741,338 Targeted delivery to human diseases and disorders
PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
WO2014167126 Platform for targeted delivery to stem cells and tumor cells and uses thereof
